Eli Lilly and Company (NYSE: LLY) and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trading Halts

Piper Jaffray Cuts Price Target on Eli Lilly & Co. (LLY) Following Announced Discontinuation of Evacetrapib October 13, 2015 8:38 AM Eli Lilly's (LLY) Reaction to Disappointing Evacetrapib Data Appears 'Overdone', Says BofA/MLOctober 12, 2015 11:30 AM Eli Lilly (LLY) Eva Failure Increases Dependence on Sola, BMO Capital NotesOctober 12, 2015 11:12 AM Eli Lilly's (LLY) Hold Rating Maintained at Deutsche Bank (MRK) (AMGN)October 12, 2015 10:14 AM Lilly's (LLY) CETP Inhibitor Disappointment Seen as Positive for Esperion (EPSR) and PCSK-9, Says RBC (REGN) (AMGN) (SNY) (MDCO) (MRK)October 12, 2015 9:13 AM UPDATE: Esperion (ESPR), Others Gains After Lilly Halts Development of Evacetrapib; Merch (MRK) FallsOctober 12, 2015 8:15 AM Eli Lilly & Co. (LLY) halted with news pendingOctober 12, 2015 7:41 AM